Phase 2 N=332 Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants Experiencing ≥1 Treatment-emergent Adverse Event (TEAE) — 104; 60 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=310 Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
Refractory and/or Unexplained Chronic Cough
Primary: Change From Baseline in 24-hour Cough Count After 12 Weeks of Intervention — 0.56; 0.47; 0.52; 0.64 Ratio btw geoMeans of 24h cough count — p== 0.0345
Phase 2 N=67 Translational Neuropsychopharmacology Research of Nicotine Addiction
Nicotine Dependence, Cigarettes
Primary: Percent Change in Blood Oxygen Level Dependent (BOLD) Signal Response — -0.09; 1.07; 0.08; 1.19 Percentage change
Phase 2 N=290 Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Kidney Transplant
Primary: The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups. — 52.45; 57.35 mL/min/1.73m2 — p=0.099
Phase 2 N=123 Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)
Rheumatoid Arthritis Interstitial Lung Disease
Primary: Number of Participants Who Developed Any Element of the Composite Endpoint — 7; 9 Participants
Phase 2 N=28 Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics
Asthma
Primary: Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With…
Phase 2 N=200 Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
Ductal Breast Carcinoma In Situ · Estrogen Receptor Positive · Invasive Breast Carcinoma
Primary: Number of Participants With Adverse Events Greater Than Grade 2 Serious Toxicity Rate, Defined as Toxicity Greater Than Grade 2 Using Common Terminology Criteria for…
Phase 2 N=107 A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Depressive Disorder, Major
Primary: Time to All-Cause Discontinuation of Study Drug — NA; NA days — p=0.5355
Phase 2 N=37 Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Head and Neck Cancer · Oral Mucositis
Primary: Incidence of Treatment Emergent AE's — 36; 12; 33; 35 Participants
Phase 2 N=132 A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure
Prehypertension · Hypertension, Stage I
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1; 1; 4; 0 Participants
Phase 2 N=150 Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
Influenza
Primary: Assess the Safety and Tolerability of a Single IV Dose of VIS410 in Participants With Uncomplicated Influenza Infection — 57.1; 34.7; 45.9; 26.0 percentage of participants
Phase 2 N=30 Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells · Blasts More Than 20 Percent of Peripheral Blood White Cells · Myelodysplastic/Myeloproliferative Neoplasm
Primary: Maximum Tolerated Dose of Ruxolitinib Phosphate (Phase I) — NA Dose in Milligrams
Phase 2 N=32 Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
Mydriasis · Dilation
Primary: Pupil Diameter (Change From Max) — -1.69; -0.69 mm — p=<0.0001
Phase 2 N=129 Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Primary: Phase 1b Primary Safety Outcome — 6; 6; 6; 6 Participants
Phase 2 N=21 Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC
Non-small Cell Lung Cancer · Non Small Cell Lung Cancer · NSCLC
Primary: Overall Response Rate (ORR) — 1 Participants